![](https://news.europawire.eu/wp-content/uploads/2023/06/Bayer-Strengthens-Precision-Oncology-Pipeline-with-Cedilla-Therapeutics-Partnership-144x144.jpg)
Not intended UK Media (IN BRIEF) Bayer and Cedilla Therapeutics have entered into an exclusive license agreement to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors for precision oncology. These inhibitors target oncogenic drivers and offer a unique method of action, … Read the full press release